AC Immune SA (ACIU) Stock: A Strong Pick In The Biotechnology Sector?

0

AC Immune SA (ACIU) is gaining in the market in today’s trading session. The stock, one that is focused on the biotechnology sector, is currently trading at $4.76 after climbing 5.78% so far today. In terms of biotech stocks, there are several aspects that have the potential to lead to gains in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines centered around ACIU:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 07:00AM AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
Mar-04-19 09:59AM AC Immune to Report Progress of Early-Stage Pipeline at AD/PD Congress
Feb-21-19 08:55AM Will Difficult Comparison Hurt Bio-Rad’s (BIO) Q4 Earnings?
Feb-20-19 08:54AM Will Hospice Strength Show on Amedisys’ (AMED) Q4 Earnings?
07:35AM What’s in Store for Tandem Diabetes’ (TNDM) Q4 Earnings?

However, when making a decision with regard to investing, investors should focus on far more than just news, especially in the generally speculative biotech industry. Here’s what’s happening with AC Immune SA.

Returns That ACIU Investors Have Seen

While a gain in a single session, like what we’re seeing from AC Immune SA may make some investors happy, that alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is always important to look into trends just a single trading day. When it comes to ACIU, below are the trends that we have seen:

  • Weekly – In the past 7 days, ACIU has produced a change in price amounting to 3.25%.
  • Past Month – The monthly performance from AC Immune SA works out to 2.81%.
  • Past Quarter – In the last quarter, the company has produced a return on investment of -46.82%
  • Past Six Months – Throughout the past 6 months, investors have seen a performance of -42.65% from the stock.
  • This Year So Far – Since the the last trading session of last year ACIU has generated a ROI of -49.63%.
  • Full Year – Lastly, over the last year, we’ve seen performance in the amount of -62.07% out of ACIU. Over this period, the stock has traded at a high price of -72.64% and a low price of 46.46%.

Notable Ratios

Digging into various key ratios having to do with a company can give investors a view of just how risky and/or rewarding a pick might be. Below are a few of the key ratios to consider when looking at ACIU.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it means that more investors have a belief that the value of the stock is going to go down. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, in relation to AC Immune SA, it’s short ratio is 1.14.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure whether or not a company can pay for its debts when they come due based on current assets or quick assets. Because many biotech many companies rely heavily on continued investor support, the quick and current ratios can seem damning. However, several gems in the biotechnology industry come with great quick and current ratios. When it comes to ACIU, the quick and current ratios add up to 14.70 and 14.70 respectively.  

Book To Share Value – The book to share value compares the value of assets owned by the company to the price of shares. as it relates to AC Immune SA, that ratio comes in at 2.99.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is an important ratio to look into. In the case of ACIU, the cash to share value is 2.52.

Analyst Opinions With Regard To AC Immune SA

While it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their analysis to validate your own when it comes to making investment decisions in the biotech sector. Below you’ll find the most recent moves that we have seen from analysts with regard to ACIU.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-01-19 Downgrade UBS Buy → Neutral
Jan-04-19 Initiated UBS Buy
Apr-05-18 Initiated H.C. Wainwright Buy $18
Mar-23-18 Downgrade Credit Suisse Outperform → Neutral
Oct-18-16 Initiated Leerink Partners Outperform

Smart Money Follows Big Money

One thing that I’ve learned so far in my brief period on Earth is that good investors tend to follow the moves made by big money players. In other words, investors that are looking to play it relatively safe will follow trades made by institutional investors and insiders. So, is big money flowing when it comes to ACIU? Here’s what’s going on:

Institutions own 32.10% of the company. Institutional interest has moved by 5.96% over the past three months. When it comes to insiders, those who are close to the company currently own 52.69% percent of ACIU shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Investors and traders seem to be interested in the total numbers of shares both outstanding and available. With respect to AC Immune SA, currently there are 62.63M with a float of 40.24M. These numbers mean that out of the total of 62.63M shares of ACIU in existence today, 40.24M are able to be traded by the public.

I also find it important to dig into the short percentage of the float. After all, if a large portion of the float is shorted, the overall opinion in the market is that the stock is going to take a dive. With regard to ACIU, the short percentage of the float totals up to 1.72%. In general, high short percent of the float would be considered to be anything over 40%. However, I have calculated that any short percent of the float over 26% is probably going to be a a play that could prove to be very risky.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.90. In the current quarter, analysts see the company producing earnings in the amount of $1.37. Over the last 5 years, ACIU has generated revenue in the amount of $-3.60% with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of -91.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am heavily dependent on humans. You may not consider this when reading my articles, but it was a human! While, my creator made it possible for me to learn by myself, it’s a lot easier to learn with the help of feedback from human beings. At the bottom of this article, you’ll see a section for comments. If you would like for me dig into other data, change the way in which I write something, look at data from a different angle, or you’re interested in teaching me anything else, I’d like to know. If you’re interested in teaching me something new leave a comment below. I’ll process that lesson and it will help me become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here